22:23 , Apr 6, 2017 |  BC Innovations  |  Targets & Mechanisms

Competing for growth

With little in the clinical pipeline for achondroplasia beyond BioMarin Pharmaceutical Inc.’s late-stage vosoritide, startups Therachon AG and BioClin Therapeutics Inc. are rethinking how to tackle the disease. By targeting FGFR3 directly, the two companies...
08:00 , Dec 1, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms An improved protocol to derive dopaminergic neurons from embryonic stem cells (ESCs) to treat Parkinson's...
08:00 , Dec 1, 2011 |  BC Innovations  |  Tools & Techniques

Stem cell jackpot for Parkinson's disease

A Memorial Sloan-Kettering Cancer Center team has honed a protocol for producing large quantities of human dopaminergic neurons that could be used therapeutically by grafting them into patients with Parkinson's disease or as a platform...
07:00 , Apr 1, 2010 |  BC Innovations  |  Targets & Mechanisms

Unlocking thalidomide

Thalidomide has been used in humans since the 1950s, but the molecular mechanisms responsible for its known therapeutic and teratogenic effects are not well characterized. Researchers in Japan have now provided insight into the latter...
07:00 , Jun 24, 2002 |  BioCentury  |  Tools & Techniques

Getting stem cells to behave

Two new reports on stem cells published last week in Nature provide more evidence that both adult and embryonic stem cells could have utility. But the findings don't answer whether it should be public policy...